Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Siggelkow, Wulf ^a   Boehm, Daniel ^b   Gebhard, Susanne ^b   Battista, Marco ^b   Sicking, Isabel ^b   Lebrecht, Antje ^b   Solbach, Christine ^b   Hellwig, Birte ^c   Rahnenführer, Jörg ^c   Koelbl, Heinz ^b   Gehrmann, Mathias ^d   Marchan, Rosemarie ^c   Cadenas, Cristina ^c   Hengstler, Jan G ^c   Schmidt, Marcus ^b  

^a Diakoniekrankenhaus Henriettenstiftung und Diakoniekrankenhaus Friederikenstift   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d BAYER AG   (Germany)

Author keywords

Aurora kinase; Aurora kinase inhibitors; Breast cancer; Node negative breast cancer; Prognosis

Indexed keywords

AURORA A KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; AURKA GENE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METAGENOMICS; METASTASIS FREE SURVIVAL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRANSCRIPTOME;

EID: 84869862236     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-562     Document Type: Article

References (38)

1. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Canc 2004, 4:927-936.
2. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Canc Res 2007, 5:1-10.
3. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-854. 10.1038/nrm1245, 14625535.
4. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. A homologue of drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998, 17:3052-3065. 10.1093/emboj/17.11.3052, 1170645, 9606188.
5. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Canc 2005, 5:42-50.
6. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JMC, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262-267. 10.1038/nm1003, 14981513.
7. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003, 161:267-280. 10.1083/jcb.200208091, 2172902, 12719470.
8. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters J. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003, 161:281-294. 10.1083/jcb.200208092, 2172906, 12707311.
9. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M. Mitotic kinase expression and colorectal cancer progression. J Natl Canc Inst 1999, 91:1160-1162.
10. Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/aurora kinase) gene and breast cancer risk (United States). Canc Causes Control 2006, 17:81-83.
11. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, Ashworth A, Peto J. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Canc Inst 2006, 98:1014-1018.
12. Dai Q, Cai Q, Shu X, Ewart-Toland A, Wen W, Balmain A, Gao Y, Zheng W. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Canc Epidemiol Biomarkers Prev 2004, 13:2065-2070.
13. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004, 279:19643-19648. 10.1074/jbc.M311780200, 14990569.
14. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Canc Res 1999, 59:2041-2044.
15. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Canc 2001, 92:370-373.
16. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung M. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004, 100:12-19. 10.1002/cncr.11879, 14692019.
17. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Canc Res 2008, 14:4455-4462.
18. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Canc Res 2008, 10:R65.
19. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 2008, 3:e2994. 10.1371/journal.pone.0002994, 2500166, 18714348.
20. van Veer L, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
21. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Canc Inst 2006, 98:262-272.
22. Teschendorff AE, Mook S, Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LFA. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Canc Res 2008, 10:R93.
23. Ali HR, Dawson S, Blows FM, Provenzano E, Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Canc 2012, 106:1798-1806.
24. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics 2008, 24:2200-2208. 10.1093/bioinformatics/btn374, 2553442, 18635567.
25. Schmidt M, Petry I, Boehm D, Gebhard S, Lebrecht A, Koelbl H, Gehrmann M, Hengstler JG. Prognostic significance of Aurora kinase A expression in three cohorts of node-negative breast cancer patients. Canc Res 2010, 70:33s.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Canc Res Treat 2006, 100:229-235.
27. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr H, Hengstler JG, Kölbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Canc Res 2008, 68:5405-5413.
28. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
29. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Canc Res 2007, 13:3207-3214.
30. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JGM, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246. 10.1200/JCO.2006.07.1522, 17401012.
31. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Canc Res 2008, 14:5158-5165.
32. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Canc Res Treat 2012, 135:301-306.
33. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H, Gehrmann M, Lehr H, Koelbl H, Hengstler JG, Schuler M. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Canc Res 2008, 14:5849-5855.
34. Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Canc Res Treat 2011, 125:637-646.
35. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SJ, Lee M. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Canc 2010, 9:42.
36. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Canc Ther 2009, 8:1808-1817.
37. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Canc Inst 2012, 104:311-325.
38. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr H, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Canc Res Offic J Am Assoc Canc Res 2012, 18:2695-2703.